Literature DB >> 3275475

Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.

P Selvanayagam1, M Blick, F Narni, P van Tuinen, D H Ledbetter, R Alexanian, G F Saunders, B Barlogie.   

Abstract

Structural alterations of the c-myc oncogene in human Burkitt's lymphoma and mouse plasmacytoma suggest that this oncogene is involved in several B cell neoplasms. The possibility of c-myc alterations in human myeloma has not been explored, probably because the low proliferative activity characteristic of this tumor impairs the propagation of representative cell lines for the performance of adequate cytogenetic studies. This report describes alterations in the c-myc locus with concomitant elevated expression of mRNA in the tumor cells of two of 37 patients with multiple myeloma. In one case, somatic cell hybrid studies revealed that the cloned rearranged DNA was entirely derived from chromosome 8, thus indicating a novel mechanism of c-myc activation different from that in Burkitt's lymphoma. Seven other patients exhibited five- to 12-fold overexpression of c-myc RNA when compared with normal marrow cells. Elevated mRNA expression in about one fourth of our patients suggests that the c-myc oncogene has a pathogenetic role in the evolution of multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3275475

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Proto-oncogene analysis in multiple myeloma.

Authors:  M Ladanyi; S Wang; R Niesvizky; H Feiner; J Michaeli
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  Multiple myeloma: biology and therapy.

Authors:  B Barlogie; J Epstein
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

4.  The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis.

Authors:  Megan Romeo; Tetiana Hutchison; Aditi Malu; Averi White; Janice Kim; Rachel Gardner; Katie Smith; Katherine Nelson; Rachel Bergeson; Ryan McKee; Carolyn Harrod; Lee Ratner; Bernhard Lüscher; Ernest Martinez; Robert Harrod
Journal:  Virology       Date:  2018-02-20       Impact factor: 3.616

5.  Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

Authors:  R G Hoover; C Lary; R Page; P Travis; R Owens; J Flick; J Kornbluth; B Barlogie
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

Review 6.  Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.

Authors:  Harmen van Andel; Kinga A Kocemba; Marcel Spaargaren; Steven T Pals
Journal:  Leukemia       Date:  2019-02-15       Impact factor: 11.528

7.  Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion.

Authors:  Kodai Kuriyama; Yutaka Enomoto; Ritsuro Suzuki; Jyuri Watanuki; Hiroki Hosoi; Yusuke Yamashita; Shogo Murata; Toshiki Mushino; Shinobu Tamura; Nobuyoshi Hanaoka; Martin Dyer; Reiner Siebert; Hiroshi Kiyonari; Hideki Nakakuma; Toshio Kitamura; Takashi Sonoki
Journal:  Int J Hematol       Date:  2017-10-25       Impact factor: 2.490

8.  The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.

Authors:  B C Millar; J B Bell; R Barfoot; M Everard
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

9.  Ras oncogene mutation in multiple myeloma.

Authors:  A Neri; J P Murphy; L Cro; D Ferrero; C Tarella; L Baldini; R Dalla-Favera
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

10.  Regulation of MYC expression and differential JQ1 sensitivity in cancer cells.

Authors:  Trent Fowler; Payel Ghatak; David H Price; Ronald Conaway; Joan Conaway; Cheng-Ming Chiang; James E Bradner; Ali Shilatifard; Ananda L Roy
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.